Literature DB >> 27318792

HMGB1 regulates IL-33 expression in acute respiratory distress syndrome.

Juan Fu1, Shi-Hui Lin1, Chuan-Jiang Wang1, Sheng-Yuan Li1, Xuan-Yun Feng1, Qiong Liu1, Fang Xu2.   

Abstract

The development and progression of acute respiratory distress syndrome (ARDS) has been shown to be regulated by cytokines. IL-33 and HMGB1 are conventionally considered as nuclear proteins and have a proinflammatory role. Studies have confirmed that HMGB1 has a significant role in ARDS, but few studies have provided direct evidence to confirm that IL33 is involved in ARDS. The purpose of our study was to determine whether IL-33 is elevated in ARDS and the relationship between IL-33 and HMGB1 in ARDS. We established a mouse model of LPS-induced lung inflammation/injury. Serum, bronchoalveolar lavage fluid (BALF) and lung tissues were obtained to determine the related indicators. IL-33 levels in both the serum, BALF and lungs were significantly increased at 24h after LPS administration compared to the control group. We also found that HMGB1 and other Th1 cytokine/chemokine levels in serum and BALF were also significantly elevated, but the Th2 cytokine levels in serum and BALF didn't increase. To further study the relationship between IL-33 and HMGB1, mice were pretreated with glycyrrhizin (an inhibitor of HMGB1) prior to LPS administration. We found that the expression of IL-33 and HMGB1 were markedly lower than those in the LPS group and the lung injury was ameliorated. The levels of other Th1 cytokines and chemokines in serum and BALF were also significantly decreased. The results showed that IL-33 is likely a major factor in ARDS, and the release of HMGB1 may be correlated with up-regulation of IL-33 expression.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute respiratory distress syndrome; Cytokine; High mobility group protein-1; Inflammation; Interleukin-33

Mesh:

Substances:

Year:  2016        PMID: 27318792     DOI: 10.1016/j.intimp.2016.06.010

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

1.  The HMGB1-RAGE axis induces apoptosis in acute respiratory distress syndrome through PERK/eIF2α/ATF4-mediated endoplasmic reticulum stress.

Authors:  Fei He; Lina Gu; Nan Cai; Jun Ni; Yong Liu; Quan Zhang; Chao Wu
Journal:  Inflamm Res       Date:  2022-07-24       Impact factor: 6.986

2.  Elevated IL-33 promotes expression of MMP2 and MMP9 via activating STAT3 in alveolar macrophages during LPS-induced acute lung injury.

Authors:  Yafeng Liang; Nengli Yang; Guoquan Pan; Bingxin Jin; Shufen Wang; Wei Ji
Journal:  Cell Mol Biol Lett       Date:  2018-10-31       Impact factor: 5.787

3.  IL-33 and its increased serum levels as an alarmin for imminent pulmonary complications in polytraumatized patients.

Authors:  Gabriel Halát; Thomas Haider; Michel Dedeyan; Thomas Heinz; Stefan Hajdu; Lukas L Negrin
Journal:  World J Emerg Surg       Date:  2019-07-19       Impact factor: 5.469

4.  Recombinant thrombomodulin protects against LPS-induced acute respiratory distress syndrome via preservation of pulmonary endothelial glycocalyx.

Authors:  Kodai Suzuki; Hideshi Okada; Genzou Takemura; Chihiro Takada; Hiroyuki Tomita; Hirohisa Yano; Isamu Muraki; Ryogen Zaikokuji; Ayumi Kuroda; Hirotsugu Fukuda; Ayane Nishio; Shigeo Takashima; Akio Suzuki; Nagisa Miyazaki; Tetsuya Fukuta; Noriaki Yamada; Takatomo Watanabe; Tomoaki Doi; Takahiro Yoshida; Keisuke Kumada; Hiroaki Ushikoshi; Shozo Yoshida; Shinji Ogura
Journal:  Br J Pharmacol       Date:  2020-07-14       Impact factor: 8.739

5.  Interplay between hypoxia and inflammation contributes to the progression and severity of respiratory viral diseases.

Authors:  Sulagna Bhattacharya; Sakshi Agarwal; Nishith M Shrimali; Prasenjit Guchhait
Journal:  Mol Aspects Med       Date:  2021-07-19

6.  Cyclic stretch induced IL-33 production through HMGB1/TLR-4 signaling pathway in murine respiratory epithelial cells.

Authors:  Jing Chang; Yuefeng Xia; Karla Wasserloos; Meihong Deng; Kory J Blose; David A Vorp; Heth R Turnquist; Timothy R Billiar; Bruce A Pitt; Ma-Zhong Zhang; Li-Ming Zhang
Journal:  PLoS One       Date:  2017-09-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.